Document is current
Any future updates will be listed below
-
Authors
McAlpine, Cameron S.
Park, Joseph
Griciuc, Ana
Kim, Eunhee
Choi, Se Hoon
Iwamoto, Yoshiko
Kiss, Máté G. https://orcid.org/0000-0002-9215-8328
Christie, Kathleen A.
Vinegoni, Claudio https://orcid.org/0000-0002-9818-3639
Poller, Wolfram C.
Mindur, John E. https://orcid.org/0000-0002-2212-3904
Chan, Christopher T.
He, Shun
Janssen, Henrike
Wong, Lai Ping
Downey, Jeffrey
Singh, Sumnima
Anzai, Atsushi https://orcid.org/0000-0002-7474-1309
Kahles, Florian
Jorfi, Mehdi https://orcid.org/0000-0003-4724-6190
Feruglio, Paolo Fumene
Sadreyev, Ruslan I.
Weissleder, Ralph https://orcid.org/0000-0003-0828-4143
Kleinstiver, Benjamin P. https://orcid.org/0000-0002-5469-0655
Nahrendorf, Matthias https://orcid.org/0000-0002-4021-1887
Tanzi, Rudolph E. https://orcid.org/0000-0002-7032-1454
Swirski, Filip K. https://orcid.org/0000-0002-3163-9152
- License Information
-
More Information
Article History
Received: 29 December 2020
Accepted: 17 June 2021
First Online: 14 July 2021
Competing interests
: C.S.M., F.K.S., and R.E.T. are inventors on a patent application filed by Mass General Brigham that describes targeting IL-3 signalling in AD (invention record no. 2020-568). B.P.K. is an inventor on patent applications filed by Mass General Brigham that describe genome engineering technologies and methods, is an advisor to Acrigen Biosciences, and consults for Avectas Inc. and ElevateBio.
